Central and peripheral testosterone effects in men with heart failure: An approach for cardiovascular research

Željko Bušić1, Viktor Čulić1

  • 1Viktor Čulić, Department of Cardiology, University Hospital Center Split, 21000 Split, Croatia.

World Journal of Cardiology
|September 29, 2015
PubMed

Insights

Testosterone

Area of Science:

  • Endocrinology
  • Cardiology
  • Physiology

Background:

  • Heart failure (HF) remains a global health challenge with significant morbidity and mortality.
  • Testosterone's role in HF is increasingly researched, with known central and peripheral effects.
  • Understanding testosterone's mechanisms is crucial for improving HF treatment.

Purpose of the Study:

  • To review and synthesize current knowledge on the effects of testosterone in heart failure (HF).
  • To differentiate between central (cardiac) and peripheral (extracardiac) actions of testosterone.
  • To highlight areas requiring further investigation regarding testosterone's cardiac effects in HF.

Main Methods:

  • Literature review of studies investigating testosterone and heart failure.
  • Categorization of testosterone effects into central (cardiac) and peripheral (extracardiac).
  • Analysis of existing data on testosterone's impact on cardiomyocytes, electrophysiology, blood vessels, baroreceptors, skeletal muscles, and erythropoiesis.

Main Results:

  • Peripheral effects of testosterone, including on blood vessels, skeletal muscles, and red blood cell production, may contribute to beneficial outcomes in HF.
  • Central effects of testosterone involve direct influences on heart cells (cardiomyocytes) and heart rhythm (electrophysiology).
  • While peripheral actions are better understood, central cardiac effects of testosterone in HF warrant deeper exploration.

Conclusions:

  • Testosterone exerts both central and peripheral effects relevant to heart failure pathophysiology.
  • Peripheral testosterone actions offer potential therapeutic insights for managing HF.
  • Further research into the direct cardiac effects of testosterone is essential for a comprehensive understanding of its role in HF.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.6K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
544
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
580